These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31420708)

  • 1. [The risk of subsequent primary cancer after radiotherapy of localised prostate cancer with carbon ions may be reduced compared to treatment with photons].
    Kraus KM; Combs SE
    Strahlenther Onkol; 2019 Nov; 195(11):1033-1035. PubMed ID: 31420708
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of subsequent primary cancers after carbon ion radiotherapy, photon radiotherapy, or surgery for localised prostate cancer: a propensity score-weighted, retrospective, cohort study.
    Mohamad O; Tabuchi T; Nitta Y; Nomoto A; Sato A; Kasuya G; Makishima H; Choy H; Yamada S; Morishima T; Tsuji H; Miyashiro I; Kamada T
    Lancet Oncol; 2019 May; 20(5):674-685. PubMed ID: 30885458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should we expand the carbon ion footprint of prostate cancer?
    Catton CN; Shultz DB
    Lancet Oncol; 2019 May; 20(5):608-609. PubMed ID: 30885459
    [No Abstract]   [Full Text] [Related]  

  • 4. Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas.
    Glowa C; Peschke P; Brons S; Neels OC; Kopka K; Debus J; Karger CP
    Radiat Oncol; 2017 Nov; 12(1):174. PubMed ID: 29121984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrinsic and extrinsic tumor characteristics are of minor relevance for the efficacy of split-dose carbon ion irradiation in three experimental prostate tumors.
    Glowa C; Peschke P; Brons S; Debus J; Karger CP
    Radiother Oncol; 2019 Apr; 133():120-124. PubMed ID: 30935567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key considerations when reviewing subsequent primary cancers following radiotherapy.
    Kishan AU; Wang C; Steinberg ML; Spratt DE
    Lancet Oncol; 2019 Jun; 20(6):e291. PubMed ID: 31162098
    [No Abstract]   [Full Text] [Related]  

  • 7. Key considerations when reviewing subsequent primary cancers following radiotherapy - Authors' reply.
    Mohamad O; Tabuchi T; Morishima T; Makishima H; Miyashiro I; Tsuji H
    Lancet Oncol; 2019 Jun; 20(6):e292. PubMed ID: 31162099
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients.
    Marvaso G; Jereczek-Fossa BA; Vischioni B; Ciardo D; Giandini T; Hasegawa A; Cattani F; Carrara M; Ciocca M; Bedini N; Villa S; Morlino S; Russo S; Zerini D; Colangione SP; Panaino CMV; Fodor C; Santoro L; Pignoli E; Valvo F; Valdagni R; De Cobelli O; Orecchia R
    Tumori; 2017 May; 103(3):314-318. PubMed ID: 28009421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Single Dose Photons and Carbon Ions on Perfusion and Vascular Permeability: A Dynamic Contrast-Enhanced MRI Pilot Study in the Anaplastic Rat Prostate Tumor R3327-AT1.
    Bendinger AL; Seyler L; Saager M; Debus C; Peschke P; Komljenovic D; Debus J; Peter J; Floca RO; Karger CP; Glowa C
    Radiat Res; 2020 Jan; 193(1):34-45. PubMed ID: 31697210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photon and carbon ion irradiation of a rat prostate carcinoma: does a higher fraction number increase the metastatic rate?
    Karger CP; Scholz M; Huber PE; Debus J; Peschke P
    Radiat Res; 2014 Jun; 181(6):623-8. PubMed ID: 24844648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative biological effectiveness of carbon ions in a rat prostate carcinoma in vivo: comparison of 1, 2, and 6 fractions.
    Karger CP; Peschke P; Scholz M; Huber PE; Debus J
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):450-5. PubMed ID: 23474116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA damage response of clinical carbon ion versus photon radiation in human glioblastoma cells.
    Lopez Perez R; Nicolay NH; Wolf JC; Frister M; Schmezer P; Weber KJ; Huber PE
    Radiother Oncol; 2019 Apr; 133():77-86. PubMed ID: 30935585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A validated tumor control probability model based on a meta-analysis of low, intermediate, and high-risk prostate cancer patients treated by photon, proton, or carbon-ion radiotherapy.
    Walsh S; Roelofs E; Kuess P; Lambin P; Jones B; Georg D; Verhaegen F
    Med Phys; 2016 Feb; 43(2):734-47. PubMed ID: 26843237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential pattern of HIF-1α expression in HNSCC cancer stem cells after carbon ion or photon irradiation: one molecular explanation of the oxygen effect.
    Wozny AS; Lauret A; Battiston-Montagne P; Guy JB; Beuve M; Cunha M; Saintigny Y; Blond E; Magne N; Lalle P; Ardail D; Alphonse G; Rodriguez-Lafrasse C
    Br J Cancer; 2017 May; 116(10):1340-1349. PubMed ID: 28407653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Heavy ion radiotherapy for prostate cancer -- the role of hormone therapy].
    Suzuki K; Matsui H; Kawamura H; Ohno T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):159-63. PubMed ID: 25743135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of clinical experiences on carbon ion radiotherapy at NIRS.
    Tsujii H; Mizoe JE; Kamada T; Baba M; Kato S; Kato H; Tsuji H; Yamada S; Yasuda S; Ohno T; Yanagi T; Hasegawa A; Sugawara T; Ezawa H; Kandatsu S; Yoshikawa K; Kishimoto R; Miyamoto T
    Radiother Oncol; 2004 Dec; 73 Suppl 2():S41-9. PubMed ID: 15971308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study.
    Shiba S; Shibuya K; Katoh H; Kaminuma T; Miyazaki M; Kakizaki S; Shirabe K; Ohno T; Nakano T
    Radiat Oncol; 2019 Aug; 14(1):137. PubMed ID: 31375120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
    Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
    Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.
    Dai Y; Wei Q; Schwager C; Hanne J; Zhou C; Herfarth K; Rieken S; Lipson KE; Debus J; Abdollahi A
    Radiat Oncol; 2018 Jan; 13(1):1. PubMed ID: 29304828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.